TB-402 is a human IgG4 anticoagulant monoclonal antibody that partially inhibits Factor VIII. It exhibits long-lasting antithrombotic effects and can be studied for the prevention of venous thromboembolism (VTE) following total knee replacement (TKR) surgery.
Target:
Factor VIII
* VAT and and shipping costs not included. Errors and price changes excepted